Epinephrine stimulates human muscle lipoprotein lipase activity in vivo

• Published in: Metabolism, clinical and experimental clinical and experimental, 1999-04, Vol.48 (4), p.461-464
• Main Authors: Pedersen, Steen B., Bak, Jens F., Holck, Palle, Schmitz, Ole, Richelsen, Bjørn
• Format: Article
• Language: English
• Subjects: Adrenergic alpha-Agonists - blood; Adrenergic alpha-Agonists - pharmacology; Adult; Biological and medical sciences; Calorimetry, Indirect; Epinephrine - blood; Epinephrine - pharmacology; Fundamental and applied biological sciences. Psychology; General aspects. Hormone interactions. Hormone actions on several organ systems. Adaptive reactions; Hormone Antagonists - pharmacology; Humans; Hypoglycemic Agents - blood; Hypoglycemic Agents - pharmacology; Insulin - blood; Insulin - pharmacology; Lipoprotein Lipase - metabolism; Male; Muscle, Skeletal - drug effects; Muscle, Skeletal - enzymology; Somatostatin - pharmacology; Stimulation, Chemical; Vertebrates: endocrinology
• ISSN: 0026-0495; 1532-8600
• DOI: 10.1016/S0026-0495(99)90104-X

Lipoprotein lipase (LPL) is involved in lipoprotein metabolism and nutrient partitioning in both adipose tissue and skeletal muscle, and LPL activity is regulated by various hormones and the nutritional state. However, the action of catecholamines has not been thoroughly investigated in humans. Therefore, the effects of exogenous epinephrine on skeletal muscle LPL (SM-LPL) activity and whole-body lipid oxidation were studied. Muscle biopsies were obtained from eight healthy subjects before, during, and after epinephrine infusion. Somatostatin was infused to suppress endogenous insulin production and insulin was infused at a constant rate to maintain basal insulin levels throughout the study. After an equilibrium period (120 minutes), epinephrine (0.05 μg/kg/min) was infused for another 120 minutes. Epinephrine stimulated SM-LPL activity by 21.8% ± 6.8% above basal levels from 1.44 ± 0.25 to 1.69 ± 0.28 μmol free fatty acid (FFA)/h/g muscle ( P < .02), increased plasma FFA 270% from 0.147 to 0.544 mmol/L ( P < .05), and increased lipid oxidation 45% from 4.37 to 6.36 mg/kg/min ( P < .05). The increase in SM-LPL activity was positively correlated with the increase in whole-body lipid oxidation ( R = .75, P < .05). Finally, lipid oxidation and SM-LPL activity were negatively correlated with whole-body glucose oxidation. Overall, the results demonstrate that epinephrine is able to stimulate SM-LPL activity in humans, and thus may have opposite effects on adipose tissue and SM-LPL activity.